Research programme: obesity therapy - BEXEL PharmaceuticalsAlternative Names: BLX-1028; BLX-2002
Latest Information Update: 05 Sep 2007
At a glance
- Originator BEXEL Pharmaceuticals
- Class Amino acids; Dipeptides; Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity